Business
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2026 World Congress on Osteoarthritis, taking place April 23-26, 2026, in West Palm Beach, Florida, USA. The presentations will feature 3-month and 6-month endpoints clinical data from the Phase IIa (
About this update from Enlivex Ltd.
[{"type":"image","alt":"Enlivex Ltd.","displaySize":"","headline":null,"caption":"Enlivex Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":157,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/ad540faa2e044a11d72e39afa60b11aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.ScqKR0EaAqUedA98JbGwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUy/https://media.zenfs.com/en/globenewswire.com/ad540faa2e044a11d72e39afa60b11aa","width":157,"height":39}},"lazy":false},{"type":"text","content":"Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2026 World Congress on Osteoarthritis, taking place April 23-26, 2026, in West Palm Beach, Florida, USA.","length":404,"tagName":"p"},{"type":"text","content":"The presentations will feature 3-month and 6-month endpoints clinical data from the Phase IIa (NCT06233474) for Allocetra™ in patients with moderate-to-severe knee osteoarthritis (KOA). The Phase IIa data demonstrated clinically meaningful and statistically significant improvement of the Allocetra™-treated arm in reduction of pain and improvement of function, compared to the control placebo arm, in idiopathic age-related osteoarthritis patients (≥60 years), representing more than 50% of the total KOA market.","length":519,"tagName":"p"},{"type":"text","content":"The data will be presented by Prof. Philip Conaghan, Consultant Rheumatologist and Director of the NIHR Leeds Biomedical Research Centre. Professor Conaghan is an international leader in osteoarthritis and musculoskeletal imaging, who has authored more than 700 publications and chaired multiple global guidelines and trial initiatives. In addition, the Company will present comprehensive pharmacological characterization data supporting the novel immunomodulating mechanism of action of AllocetraTM.","length":500,"tagName":"p"},{"type":"text","content":"Oren Hershkovitz, Ph.D, CEO of Enlivex, commented "We are pleased that the OARSI 2026 team selected Enlivex to present this data at the 2026 World Congress on Osteoarthritis, which is the leading international congress on the topic of osteoarthritis. We look forward to pr...